Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study
Hanmei Lou,
Hongbing Cai,
Xin Huang
et al.
Abstract:Purpose: Immune checkpoint inhibitors (ICIs) have been potential treatment option for patients with cervical cancer in several clinical studies. We investigated the safety and efficacy of cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4, plus standard therapy for the first-line treatment of R/M CC. Patients and Methods: Eligible patients were assigned to 3 cohorts: cohort A-15 (cadonilimab 15mg/kg every 3 weeks (Q3W) plus chemotherapy), cohort A-10 (cadonilimb 10mg/kg Q3W plus chemotherapy), and co… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.